People who needs CVBP (Central Venous Blood Pressure Measurement).
Intensive Care Units (ICU) Heart attack Catheterization: Expensive & Risky, Procedure Potential Problems: Infections, Fluid shifts. Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: ValueProposition A painless, low cost, technology to measure CVBP. Stake Holder Patient and his Family Physician & Nurse Payers (Public & Private) Hospitals Government Regulator Value Created Lessen Pain and suffering Less en Lawsuitsfor wrong catheterizations. Reduce the currentCost of the procedure Increase the productivity (faciilities) Secure and effective treatments (Law/Reg.) Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: Technology A disruptive non-invasive technology that measure CVBP (Lab scale prototype is ready!!!!) Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: TechnologyCompetitiveness Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: MarketOpportunity PotentialMarket: US Market (ICU Beds) CAGR 12.3% Hospitals2 2,754 BPS-Cardicac: $4,000 $491 MUSD Beds in Hospitals2 951,045 Intensive Care Beds2 122,810 BCC Research Report Code HLC019D, Published: August 2009 includes, equipment disposal and services. (2) American Hospital Association: Fast Facts on US Hospitals 2009 report. Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: Business Model Goal: License the technology to a major Medical Device Manufacturer GE Medical Systems Johnson & Johnson Medical System Baxter Where We add value to the Business Model? Disruptive Technology Patent Exclusivity for US/Mexico Markets Regulatory Compliance Paperwork USPTO, FDA, COFEPRIS Clinical trials Manufacturing & Testing (1,000 Units) Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: TheTeam Fernando Huerta Marco Sanchez Viridiana Omana Michele Gonzalez Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: Financials (ValueCreation) Product Target Market US/Mex: Units Solds: 28,179 Revenue: $112M usd Royalties: $13.5 M usd NPV @12%: Investors, Founders & MDM: $28.6M usd Investors: 4.0 M usd Founders: $9.4M usd Medical Device Manufacturer: 15.2M usd Payback: Investors & Founders: 3.9 years Device Manufacter: 1.2 years Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: Funds Required VC investment in Medical Devices Startups $719MUSD / Q4 2009 $ 1.56 MUSD Equity: 30% Funds used for: a) Exclusivity (US/Mex) b) FDA/COFEPRIS Approvals c) USPTO filing d) Clinical Trials e) Manufacturer 1,000 units f) Due diligence for contracting MDM Exit: Selling IP to a major Medical Device Manufacturer. Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS-Cardiac: Status Negotiation: Medical Dev. Manufacturer (MDM) Licensing contract signed MDM Ready for Sale. Manufacturing 1,000 Units Clinical Trials FDA/COFEPRIS Approvals Raise Funds: $1.56 MUSD IP Filing US/Mex Massive Commercialization Raising Capital $1.56 MUSD R&D Royalties 2005 – 2009 2010 2011 2012 2013 Pain Val. Prop. Tech. Mkt. Opp. Bus. Mod. Team Fin. Status
BPS Cardiac: Remember!!!!!! This is an Excellent Opportunity to invest in a non-invasive low risk disruptive technology that saves people lives. Business Upsides: More applications, can be expanded worldwide and with a potential of developing a recurrent business disposals. That requires an investment of $1.56 MUSD used for key success activities. (IP Lawers and filing and device manufacturing) And creates an economic value of $28.6M USD.